In EDS ansehen

Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases

Gespeichert in:
Bibliographische Detailangaben
Titel: Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Autoren: Maja Thiele, Ida Falk Villesen, Lili Niu, Stine Johansen, Karolina Sulek, Suguru Nishijima, Lore Van Espen, Marisa Keller, Mads Israelsen, Tommi Suvitaival, Andressa de Zawadzki, Helene Bæk Juel, Maximilian Joseph Brol, Sara Elizabeth Stinson, Yun Huang, Maria Camilla Alvarez Silva, Michael Kuhn, Ema Anastasiadou, Diana Julie Leeming, Morten Karsdal, Jelle Matthijnssens, Manimozhiyan Arumugam, Louise Torp Dalgaard, Cristina Legido-Quigley, Matthias Mann, Jonel Trebicka, Peer Bork, Lars Juhl Jensen, Torben Hansen, Aleksander Krag, Hans Israelsen, Hans Olav Melberg
Quelle: Thiele, M, Villesen, I F, Niu, L, Johansen, S, Sulek, K, Nishijima, S, Espen, L V, Keller, M, Israelsen, M, Suvitaival, T, Zawadzki, A D, Juel, H B, Brol, M J, Stinson, S E, Huang, Y, Silva, M C A, Kuhn, M, Anastasiadou, E, Leeming, D J, Karsdal, M, Matthijnssens, J, Arumugam, M, Dalgaard, L T, Legido-Quigley, C, Mann, M, Trebicka, J, Bork, P, Jensen, L J, Hansen, T, Krag, A, MicrobLiver Consortium & GALAXY Consortium 2024, ' Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases ', Journal of Hepatology, vol. 81, no. 2, pp. 345-359 . https://doi.org/10.1016/j.jhep.2024.03.035
Journal of Hepatology
Verlagsinformationen: Elsevier BV, 2024.
Publikationsjahr: 2024
Schlagwörter: Proteomics, viromics, microbiome, ALCOHOL, Biomarkers/analysis, GUT MICROBIOME, VALIDATION, 1117 Public Health and Health Services, VIROME, proteomics, Genetics, Metabolomics/methods, FIBROSIS, Humans, Metabolomics, genetics, GENOME-WIDE ASSOCIATION, GALAXY consortium, Fatty Liver/diagnosis, metagenomics, Science & Technology, metatranscriptomics, Gastroenterology & Hepatology, Non-invasive test, NONALCOHOLIC STEATOHEPATITIS, 3202 Clinical sciences, INCREASED INTESTINAL PERMEABILITY, 1103 Clinical Sciences, Genomics, metabolomics, Genomics/methods, 3. Good health, Fatty Liver, SYSTEMS BIOLOGY, lipidomics, MicrobLiver consortium, Viromics, MULTI-OMICS, Metagenomics, Microbiome, Proteomics/methods, Life Sciences & Biomedicine, Biomarkers
Beschreibung: The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to apply technological advances to clinical needs, for instance in the development of precision biomarkers for personalised medicine. Via omics technologies, biological processes from the genes to circulating protein, as well as the microbiome - including bacteria, viruses and fungi, can be investigated on an axis. However, there are important barriers to omics-based biomarker discovery and validation, including the use of semi-quantitative measurements from untargeted platforms, which may exhibit high analytical, inter- and intra-individual variance. Standardising methods and the need to validate them across diverse populations presents a challenge, partly due to disease complexity and the dynamic nature of biomarker expression at different disease stages. Lack of validity causes lost opportunities when studies fail to provide the knowledge needed for regulatory approvals, all of which contributes to a delayed translation of these discoveries into clinical practice. While no omics-based biomarkers have matured to clinical implementation, the extent of data generated has enabled the hypothesis-free discovery of a plethora of candidate biomarkers that warrant further validation. To explore the many opportunities of omics technologies, hepatologists need detailed knowledge of commonalities and differences between the various omics layers, and both the barriers to and advantages of these approaches.
Publikationsart: Article
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2024.03.035
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38552880
https://lirias.kuleuven.be/handle/20.500.12942/740356
https://doi.org/10.1016/j.jhep.2024.03.035
https://curis.ku.dk/ws/files/400206035/1_s2.0_S0168827824002198_main.pdf
https://portal.findresearcher.sdu.dk/da/publications/14c4e941-2b9a-403a-9206-c88f75ebec1f
https://doi.org/10.1016/j.jhep.2024.03.035
Rights: CC BY
Elsevier TDM
Dokumentencode: edsair.doi.dedup.....b56fec32f3bc666f16a9c5b0ab8bf938
Datenbank: OpenAIRE
Beschreibung
Abstract:The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to apply technological advances to clinical needs, for instance in the development of precision biomarkers for personalised medicine. Via omics technologies, biological processes from the genes to circulating protein, as well as the microbiome - including bacteria, viruses and fungi, can be investigated on an axis. However, there are important barriers to omics-based biomarker discovery and validation, including the use of semi-quantitative measurements from untargeted platforms, which may exhibit high analytical, inter- and intra-individual variance. Standardising methods and the need to validate them across diverse populations presents a challenge, partly due to disease complexity and the dynamic nature of biomarker expression at different disease stages. Lack of validity causes lost opportunities when studies fail to provide the knowledge needed for regulatory approvals, all of which contributes to a delayed translation of these discoveries into clinical practice. While no omics-based biomarkers have matured to clinical implementation, the extent of data generated has enabled the hypothesis-free discovery of a plethora of candidate biomarkers that warrant further validation. To explore the many opportunities of omics technologies, hepatologists need detailed knowledge of commonalities and differences between the various omics layers, and both the barriers to and advantages of these approaches.
ISSN:01688278
DOI:10.1016/j.jhep.2024.03.035